Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois Johns Hopkins University, Baltimore, Maryland University of North Carolina, Chapel Hill, North Carolina Sarah Cannon Research Institute, Nashville, Tennessee Texas Oncology, P.A., Dallas, Texas UT Southwestern Medical Center, Dallas, Texas The University of Texas Health Science Center at San Antonio, San Antonio, Texas